Meet Allied Medicine Ltd. A team of scientific, translational and clinical researchers pushing the boundaries of liquid biopsies in cancer. The team will deliver an exquisitely sensitive cancer blood test which will facilitate best-in-class identification of minimal residual disease and cancer relapse, helping clinicians confidently establish responders and non-responders to existing and novel therapies. The Team Image Harveer Dev Radek Lach About Me I am a Group leader and academic urologist in the University of Cambridge Early Cancer Institute. My group studies the molecular basis of cancer, using genetic and epigenetic insights to define tumour-specific alterations that can be used for disease detection and therapeutic stratification. Problem Existing methods to track a person's response to cancer treatment can be inaccurate, invasive and expensive. Solution To transform healthcare and expand drug eligibility through a high sensitivity low cost cancer-specific blood test. Market Healthcare providers and pharmaceutical companies looking for accurate ways to demonstrate response to existing and novel therapies, in standard of care and trial settings. Contact Harveer Dev LinkedIn Image This article was published on 2024-09-30